Hepatitis C | Clinical Medicine

Overview

Ninja Nerd details Hepatitis C (HCV), an enveloped, positive-sense single-stranded RNA virus characterized by its lack of a 3'-5' exonuclease activity, leading to high mutation rates and antigenic variation. This variability prevents effective antibody clearance, resulting in an 80% chronicity rate. The video covers HCV's transmission via blood, its replication cycle involving viral enzymes like NS3/4A (protease) and NS5B (RNA polymerase), the development of direct-acting antivirals targeting these enzymes, and the long-term consequences of chronic infection, including cirrhosis and hepatocellular carcinoma.

Key takeaways

Hepatitis C virus's lack of proofreading (3'-5' exonuclease activity) leads to high mutation rates and antigenic variation, making immune clearance difficult and resulting in 80% chronic infection.
Direct-acting antivirals (DAAs) are highly effective treatments that target specific viral enzymes: NS3/4A (protease inhibitors, -previr), NS5A (organizer, -asvir), and NS5B (RNA polymerase, -buvir).
Chronic Hepatitis C is often asymptomatic but can progress over decades to cirrhosis and hepatocellular carcinoma, necessitating regular screening and surveillance.
Hepatocyte damage in Hepatitis C is primarily immune-mediated, caused by cytotoxic T cells responding to viral antigens presented on infected cells.
Before starting DAAs for Hepatitis C, it is crucial to rule out Hepatitis B coinfection to prevent potentially fatal reactivation of HBV.

Chapters

0:00 Hepatitis C Virus: Structure and Genetic Instability

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus.
Unlike other RNA polymerases, HCV's RNA-dependent RNA polymerase (NS5B) lacks 3'-5' exonuclease activity.
This deficiency leads to frequent mutations and antigenic variation, hindering immune clearance and antibody recognition.
The inability to clear the virus results in an 80% rate of chronic infection.

12:19 HCV Transmission and Entry into Hepatocytes

HCV is primarily transmitted through blood, with common routes including IV drug abuse and needle-stick exposures.
Vertical transmission from mother to baby via the placenta is also a possibility.
The virus enters hepatocytes via endocytosis and undergoes uncoating to release its RNA genome.
The positive-sense single-stranded RNA is translated by host ribosomes into a polyprotein.

16:48 Viral Polyprotein Processing and Enzyme Synthesis

The viral polyprotein is cleaved by a protease, NS3/4A, into functional non-structural proteins.
Key enzymes produced include NS5A (organizer of replication and assembly) and NS5B (RNA-dependent RNA polymerase).
NS5A assists NS5B by holding it in place at the rough endoplasmic reticulum, enhancing RNA replication.
The replication process generates new viral RNA, which is then packaged with capsid proteins.

22:34 Viral Assembly and Release

Viral RNA and capsid proteins migrate to lipid droplets within hepatocytes, utilizing the VLDL pathway for assembly.
This process allows the virus to acquire apolipoproteins like apoE and apoB in its envelope.
Newly assembled virions bud from the cell membrane, leading to viremia (virus in the bloodstream).
The high mutation rate due to the lack of proofreading contributes to antigenic variation in the viral envelope proteins.

25:08 Direct-Acting Antivirals Targeting Viral Enzymes

Direct-acting antivirals (DAAs) are crucial for treating HCV by inhibiting viral enzymes.
NS3/4A inhibitors (ending in -previr, e.g., glecaprevir) block polyprotein cleavage, halting viral protein synthesis.
NS5A inhibitors (ending in -asvir, e.g., pibrentasvir, velpatasvir) disrupt replication and assembly by interfering with NS5A's function.
NS5B inhibitors (ending in -buvir, e.g., sofosbuvir) target the RNA polymerase, preventing RNA replication.

32:07 Hepatocyte Damage and Immune Response

Hepatocytes are primarily damaged not by the virus itself, but by the host's immune response, specifically cytotoxic T cells (CD8+).
Viral antigens expressed on MHC-1 molecules trigger CD8+ T cells to release perforins and granzymes, inducing apoptosis.
This immune-mediated cell death leads to acute hepatitis.
The virus's ability to evade immune clearance due to antigenic variation contributes to chronicity.

37:17 Acute Hepatitis Presentation and Chronic Infection

Acute hepatitis C is often asymptomatic, but can present with elevated AST/ALT levels (often >1000) and mild hyperbilirubinemia.
Jaundice, scleral icterus, and dark urine may occur due to impaired bilirubin conjugation and excretion.
Pale stools result from reduced bilirubin reaching the intestines, leading to less stercobilin.
Approximately 80% of individuals develop chronic hepatitis C due to insufficient viral clearance.

48:27 Chronic Hepatitis C: Asymptomatic Progression and Complications

Chronic HCV is typically asymptomatic, with only subtly elevated liver function tests (LFTs).
Over 20-30 years, chronic inflammation leads to fibrosis and can progress to cirrhosis.
Cirrhosis can cause portal hypertension (ascites, esophageal varices, splenomegaly) and impaired liver synthetic function (coagulopathy, encephalopathy).
Cirrhosis significantly increases the risk of hepatocellular carcinoma (HCC), often detected via ultrasound and elevated AFP.

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Ninja Nerd.